Developer of assays for diagnostics of cancer. It offers molecular amplification technology to detect DNA sequence variants that are used to track cancer mutations in patients' tissue or liquid biopsies. Founded in 2021, headquartered in Uppsala, Sweden. The company has raised $7.5M in funding at the series a stage. The team comprises 26 (Jun 30, 2026) employees. Backed by investors including Navigare Ventures, Novalis Biotech, UU Invest. The company is tagged with Tech, Enterprise. Rarity Biosc The company operates in Life Sciences > Clinical Genomics, Life Sciences > Oncology, Life Sciences > Genomics. Its business models include Oncology > In-Vitro Diagnostic Tests > Diversified, Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA. Founded in 2021. Headquartered in Sweden, Uppsala. The company has raised funding at the Series A stage. Backed by investors including Navigare Ventures, Novalis Biotech, UU Invest.
← All startups
Rarity Bioscience
Series ADeveloper of assays for diagnostics of cancer. It offers molecular amplification technology to detect DNA sequence variants that are used to track cancer mutations in patients' tissue or liquid biopsies. Founded in 2021, headquartered in Uppsala, Sweden. The company has raised $7.5M in funding at the series a stage. The team comprises 26 (Jun 30, 2026) employees. Backed by investors including Navigare Ventures,…
About
Business model
Oncology > In-Vitro Diagnostic Tests > Diversified,
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Liquid Biopsy > DNA
Institutional investors
Navigare VenturesNovalis BiotechUU Invest
Latest coverage
📰 See all funding news — keep up with the raises that set comps.
Investor directory
🗂️ Full list of active funds — filter by stage, check size, and geography.